Dienogest Therapy as a Treatment for Catamenial Pneumothorax: Case Report and Review of Hormonal Options

Lalani S, Shifana Lalani, Amanda Black, Meryl C Hodge, Hodge MC, Meryl Hodge, Togas Tulandi, Tulandi T, Innie Chen
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC · 2017 · vol. 39(9) , pp. 764–768 · doi:10.1016/j.jogc.2017.01.014 · PMID:28647447 · W2715113768
review OA: closed CC0 ⤵ 4 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This case report describes the successful use of dienogest to treat catamenial pneumothorax and reviews other hormonal treatment options for this condition.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BackgroundCatamenial pneumothorax is a rare but serious condition for women of reproductive age. We describe a trial of dienogest as hormonal therapy for catamenial pneumothorax and review the literature on hormonal suppressive therapy for this condition.CaseA 39-year-old female, gravida 0 para 0, presented with recurrent pneumothoraces coinciding with her menses. After surgical therapy, she was started on leuprolide acetate injections for 6 months to reduce recurrence. To reduce long-term side effects of leuprolide acetate, the patient was started on dienogest 4 mg orally once daily instead of leuprolide acetate for hormonal suppression and experienced resolution of recurrent pneumothoraces.ConclusionFor women with recurrent catamenial pneumothorax, dienogest may be an effective hormonal treatment option and alternative to long-term GnRH agonist therapy for long-term suppression.

My notes (saved in your browser only)

MeSH descriptors

Hormone Antagonists Leuprolide Nandrolone Pneumothorax Adult Female Hormone Antagonists Humans Leuprolide Nandrolone Nandrolone Pneumothorax

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (49)

Cited by (4)

Source provenance

europepmc
last seen: 2026-09-13T09:25:22.628771+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:20:25.745717+00:00
License: CC0 · commercial use OK